Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57*cytotoxic T cells as predictors of outcome
Linda Mileshkin, Dirk Honemann, Peter Gambell, Melanie Trivett, Yoshihiro Hayakawa, Mark Smyth, Victoria Beshay, David Ritchie, Paul Simmons, Alvin D Milner, Jerome B Zeldis, H Miles Prince
HAEMATOLOGICA | FERRATA STORTI FOUNDATION | Published : 2007
BACKGROUND AND OBJECTIVES: In vitro studies suggest that thalidomide has an immunoregulatory role and alters the marrow microenvironment. We assessed laboratory and clinical parameters in patients with myeloma treated with thalidomide as potential prognostic markers and looked for changes with therapy. DESIGN AND METHODS: Seventy-five patients with relapsed/refractory myeloma received thalidomide in a phase II trial. Serial samples of platelet-poor plasma and bone marrow were tested for angiogenic cytokines including vascular endothelial growth factor (VEGF), marrow microvessel-density (MVD), mast cells and CD57+ cell expression. The effects of these parameters on response rate (RR), progres..View full abstract
dr. Mileshkin was supported by the Medical Oncology Group of Australia/Novartis Clinical Research Fellowship.